These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. Martin S; Wright CM; Scott LM Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700 [TBL] [Abstract][Full Text] [Related]
23. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms]. Araki M Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708 [TBL] [Abstract][Full Text] [Related]
24. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Belcic Mikic T; Pajic T; Sever M Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869 [TBL] [Abstract][Full Text] [Related]
25. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice. Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445 [TBL] [Abstract][Full Text] [Related]
26. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Araki M; Komatsu N Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795 [TBL] [Abstract][Full Text] [Related]
27. The role of calreticulin mutations in myeloproliferative neoplasms. Araki M; Komatsu N Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992 [TBL] [Abstract][Full Text] [Related]
28. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia. Wang J; Hao J; He N; Ji C; Ma D Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485 [TBL] [Abstract][Full Text] [Related]
30. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497 [TBL] [Abstract][Full Text] [Related]
31. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
32. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372 [TBL] [Abstract][Full Text] [Related]
33. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169 [TBL] [Abstract][Full Text] [Related]
34. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ha JS; Kim YK Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276 [TBL] [Abstract][Full Text] [Related]
35. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356 [TBL] [Abstract][Full Text] [Related]
36. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing. Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176 [TBL] [Abstract][Full Text] [Related]
37. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients. Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853 [TBL] [Abstract][Full Text] [Related]
38. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting. Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531 [TBL] [Abstract][Full Text] [Related]
39. Genetic-pathologic characterization of myeloproliferative neoplasms. Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979 [TBL] [Abstract][Full Text] [Related]
40. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms. Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]